# Ipamorelin FAQ — Frequently Asked Questions From the Research Literature

> Ipamorelin questions answered from the published peer-reviewed record — mechanism, selectivity, half-life, IGF-1, bone, GI motility, regulatory status, and more.

## Mechanism and What It Does

**What does ipamorelin do?**
Ipamorelin is a pentapeptide that selectively binds the ghrelin/GHS-R1a receptor on pituitary somatotrophs, prompting pulsatile growth hormone release. At doses producing robust GH release in rat and swine models, it did not significantly elevate ACTH, cortisol, or prolactin — a selectivity profile not shared by earlier GH-releasing peptides [1].

**What is ipamorelin and how does it work?**
Ipamorelin (NNC 26-0161) is a synthetic pentapeptide with sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It acts as a selective agonist of GHS-R1a, triggering pulsatile GH release from somatotrophs through Gq/11 calcium mobilization. First described by Raun et al. (1998), it was characterized as the first GHS with selectivity comparable to GHRH [1].

**Is ipamorelin the first selective growth hormone secretagogue?**
The 1998 Raun et al. paper in European Journal of Endocrinology characterized ipamorelin as the first GHS that did not significantly elevate ACTH, cortisol, or prolactin — distinguishing it from GHRP-6 and GHRP-2. At doses exceeding 200-fold the GH-releasing ED50, cortisol and prolactin remained unaffected [1].

**What is the effect of ipamorelin on growth hormone release in research models?**
Ipamorelin produces dose-dependent, pulsatile GH release in rat and swine models and in primary rat pituitary cell cultures. In vivo doses of 2.3–80 nmol/kg IV produced robust, dose-dependent GH release; in vitro EC50 was approximately 1.3 nmol/L. Peak GH response occurs within 15–30 minutes of subcutaneous administration in published animal studies [1].

## Safety and Side Effects

**What are the risks of ipamorelin?**
In preclinical models, ipamorelin at research doses showed a favorable tolerability profile. Cortisol and prolactin were not significantly elevated [1][2]. Injection-site reactions and transient flushing have been noted in early-phase human studies. The Phase 2 human trial (NCT00672074) reported no serious adverse reactions attributed to ipamorelin [11]. The GH-independent adiposity finding (increased fat pad weight and leptin in mice) is a potential metabolic consideration [10].

**Does ipamorelin raise cortisol or prolactin levels?**
Raun et al. (1998) showed ipamorelin did not significantly elevate ACTH, cortisol, or prolactin in rat and swine models at doses producing robust GH release. This remained true at doses exceeding 200-fold the GH-releasing ED50 — the defining selectivity finding distinguishing ipamorelin from GHRP-2 and GHRP-6 [1][2].

**Does ipamorelin increase appetite the way GHRP-6 does?**
GHRP-6 strongly stimulates ghrelin-mediated appetite pathways. Ipamorelin's receptor selectivity profile results in substantially less orexigenic activity in preclinical models; human appetite data is limited. The Lall et al. (2001) study did show increased food intake and leptin in normal mice treated with ipamorelin, though less pronounced than GHRP-6 orexigenic effects [10].

**Does ipamorelin reduce belly fat?**
Direct belly-fat reduction by ipamorelin alone has not been demonstrated in controlled human trials. In rodent models, GH secretagogues influence lipolysis pathways, but the Lall et al. (2001) study showed GH-independent increases in fat pad weight and leptin in both GH-deficient and GH-intact mice treated with ipamorelin — complicating the simple lipolysis narrative [10].

**Does ipamorelin affect testosterone levels?**
Published research does not document a direct testosterone-stimulating effect from ipamorelin. GH secretagogues act on the somatotropic axis, not the hypothalamic-pituitary-gonadal axis; testosterone was not a measured endpoint in any published ipamorelin study [1].

**Is the pulsatile nature of ipamorelin safer than exogenous GH from a research perspective?**
Ipamorelin preserves pulsatility and requires intact pituitary function; exogenous GH produces continuous elevation that bypasses somatostatin feedback. Researchers have theorized this mechanistic difference may carry different safety implications [17]. Direct long-term controlled human comparison data is absent from the published literature.

## Pharmacokinetics and Dosing

**What is the half-life of ipamorelin and how does it affect dosing frequency?**
Ipamorelin has a short plasma half-life in rat models, with biexponential plasma concentration decline after IV bolus (Johansen et al. 1998, PMID 9879640) [9]. The brief duration supports the multiple-injections-per-day approach used in most published animal protocols. Human pharmacokinetic data for subcutaneous administration is not available from published studies.

**How long does it take for ipamorelin to show results in research subjects?**
In animal models, acute GH elevation is observed within 15–30 minutes of injection; the pulse resolves within hours. Downstream IGF-1 changes appear after multi-week dosing: the Johansen 1999 bone growth study ran 15 days; the Andersen 2001 bone model ran 3 months [3][4]. Controlled human timeline data for GH, IGF-1, or anabolic endpoints does not exist in the published literature.

**Does ipamorelin need to be cycled to avoid receptor desensitization?**
Jiménez-Reina et al. (2002) showed 21-day chronic ipamorelin treatment did not produce tachyphylaxis in rats — somatotrophs from treated animals showed enhanced in vitro GH response to subsequent ipamorelin challenge [7]. Long-term desensitization data beyond 21 days is not published. Controlled human data on optimal cycle length is absent from the peer-reviewed literature.

## Comparisons

**Which is better — tesamorelin, sermorelin, or ipamorelin?**
Tesamorelin is FDA-approved for HIV-associated lipodystrophy at 2 mg SC daily; sermorelin is a GHRH analog; ipamorelin is a GHRP acting at GHS-R1a. They differ in receptor target, pulsatility profile, and studied indications. A like-for-like efficacy comparison does not exist in the published record; tesamorelin is the only one of the three with an FDA-reviewed clinical indication [1][14].

**How does ipamorelin compare to GHRP-6 in terms of selectivity and side effects?**
At equimolar doses, GHRP-6 raised cortisol and ACTH significantly; ipamorelin produced equivalent GH release without these hormone elevations. GHRP-6 activates appetite-stimulating ghrelin pathways more broadly; ipamorelin's selectivity at GHS-R1a produces cleaner GH pulses in preclinical models [1][2].

**How does the ipamorelin and CJC-1295 stack produce synergistic GH release?**
CJC-1295 acts at GHRHR via cAMP/PKA; ipamorelin acts at GHS-R1a via Gq/11/calcium. Both converge on somatotroph GH exocytosis. Co-activating two complementary pathways produces GH release greater than either peptide alone in preclinical models [16][18][19].

## Regulatory and Clinical Status

**Is ipamorelin FDA approved?**
Ipamorelin is not FDA approved for any indication. It completed one Phase 2 clinical trial (NCT00672074, n=117) for postoperative ileus that did not meet its primary efficacy endpoint. It is classified as a research chemical. Compounding pharmacy classification has shifted since 2023 and remains in regulatory flux as of early 2026 [11].

**Is ipamorelin effective for postoperative ileus in research?**
Venkova et al. (2009) reported ipamorelin accelerated recovery of gastrointestinal contractile function after postoperative ileus in animal models [6]. In the Phase 2 human trial (NCT00672074, n=117), median time to first tolerated meal was 25.3 h (ipamorelin) vs 32.6 h (placebo); the difference did not reach statistical significance (p=0.15) [11].

**Does ipamorelin raise IGF-1 levels on a blood test?**
Preclinical models show sustained ipamorelin dosing increases circulating IGF-1 as a downstream consequence of elevated GH pulses [8][22]. In the Malmlöf et al. (1999) model, ipamorelin prevented glucocorticoid-associated IGF-1 decline. Individual responsiveness varies; no controlled human IGF-1 response data for ipamorelin exists in published trials.

## References

[1] Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/
[2] Raun K, et al. Ipamorelin selectivity data: GHRP-2 and GHRP-6 comparison. Eur J Endocrinol. 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/
[3] Johansen PB, et al. Ipamorelin induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106–113. https://pubmed.ncbi.nlm.nih.gov/10373343/
[4] Andersen NB, et al. Ipamorelin counteracts glucocorticoid-induced decrease in bone formation. Growth Horm IGF Res. 2001;11(5):266–272. https://pubmed.ncbi.nlm.nih.gov/11735244/
[6] Venkova K, et al. Efficacy of ipamorelin in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110–1116. https://pubmed.ncbi.nlm.nih.gov/19289567/
[7] Jiménez-Reina L, et al. Chronic ipamorelin treatment in young female rats: somatotroph response in vitro. Histol Histopathol. 2002;17(3):707–714. https://pubmed.ncbi.nlm.nih.gov/12168778/
[8] Malmlöf K, et al. Methylprednisolone does not inhibit GH release after ipamorelin in rats. Growth Horm IGF Res. 1999;9(6):396–403. https://pubmed.ncbi.nlm.nih.gov/10629165/
[9] Johansen PB, et al. Pharmacokinetics of ipamorelin with emphasis on nasal absorption. Xenobiotica. 1998;28(11):1083–1091. https://pubmed.ncbi.nlm.nih.gov/9879640/
[10] Lall S, et al. GH-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001;280(1):132–138. https://pubmed.ncbi.nlm.nih.gov/11162489/
[11] Bochicchio GV, et al. Ipamorelin for management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014. https://link.springer.com/article/10.1007/s00384-014-2030-8
[14] NIH NLM. Tesamorelin — LiverTox. NIH Bookshelf. 2023. https://www.ncbi.nlm.nih.gov/books/NBK548730/
[16] Raun K, et al. Ipamorelin — GHS-R1a vs GHRHR receptor family distinction. Eur J Endocrinol. 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/
[17] Raun K, et al. Ipamorelin — somatostatin feedback mechanism. Eur J Endocrinol. 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/
[18] Frohman LA, Kineman RD. Pulsatile GH secretion persists during continuous CJC-1295 stimulation. J Clin Endocrinol Metab. 2006. https://pubmed.ncbi.nlm.nih.gov/17018654/
[19] Sackmann-Sala L, et al. Activation of GH/IGF-1 axis by CJC-1295 in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471–477. https://pubmed.ncbi.nlm.nih.gov/19386527/
[22] Malmlöf K, et al. Methylprednisolone does not inhibit GH release — IGF-1 elevation finding. Growth Horm IGF Res. 1999;9(6):396–403. https://pubmed.ncbi.nlm.nih.gov/10629165/

---

A pastel-cloud reading of the ipamorelin literature — soft pulsatile pharmacology summarized from the peer-reviewed record, held by no clinic and sold by no one.